 SOUTH SAN FRANCISCO, Calif., May 10, 2021 PRNewswire -- IDEAYA Biosciences, Inc. NASDAQ: IDYA, a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced dose expansion of the ongoing Phase 12 study ClinicalTrials.gov Identifier: NCT03947385 evaluating the combination of darovasertib and crizotinib in metastatic uveal melanoma MUM. 